Introduction And Objectives: Continuous monitoring for hepatocellular carcinoma is necessary following treatment with direct-acting antivirals in patients with hepatitis C virus infection. We investigated whether the long-term follow-up of serum autotaxin levels could predict the development of hepatocellular carcinoma.
Patients And Methods: This prospective observational study enrolled adult patients with chronic hepatitis C virus infection who presented to the study center from January 2016 to March 2021. Among the patients who achieved a sustained viral response, the relationship between the development of hepatocellular carcinoma and serum autotaxin levels was assessed before treatment with direct-acting antivirals; at the end of therapy; at 12 and 24 weeks; and at 12, 24, 36, and 48 months after treatment.
Results: Data were analyzed for 139 patients. Thirteen patients developed hepatocellular carcinoma 48 months after treatment. The cut-off serum autotaxin values that predicted hepatocellular carcinoma after 24 weeks were 1.22 (men) and 1.92 (women) mg/L. The area under the curve for serum autotaxin was 0.83 (95% confidence interval [CI]:0.71-0.95) in men and 0.90 (95% CI: 0.82-0.99) in women. The positive predictive value of serum autotaxin was 0.208 (95% CI: 0.139-0.248), and the negative predictive value was 0.971 (95% CI: 0.939-0.990). The cumulative incidence of hepatocellular carcinoma was significantly higher when serum autotaxin levels were above the cut-off value after 24 weeks (p < 0.0001).
Conclusions: Serum autotaxin is a candidate biomarker for predicting hepatocellular carcinoma during the long-term follow-up of patients with a sustained viral response following treatment with direct-acting antivirals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aohep.2022.100660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
J Gastroenterol
November 2024
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, 3-1-69, Inabaso, Amagasaki, Hyogo, 660-8511, Japan.
Background: The histological improvement in liver fibrosis in patients with hepatitis C who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) treatment has not been comprehensively investigated. Therefore, we assessed the histological changes in liver fibrosis among patients with hepatitis C who underwent long-term follow-up after achieving SVR to treatment with DAA.
Methods: This retrospective study enrolled 71 patients with hepatitis C who achieved SVR to treatment with DAA.
Serum autotaxin positively associates with hypertension in postmenopausal women: a single center study in China.
J Hypertens
October 2024
Department of Gastroenterology.
Aim: Autotaxin is an adipokine involved in metabolic disorders. The aim of the current study was to evaluate serum autotaxin levels in hypertensive postmenopausal women and establish a relationship between autotaxin and other comorbidities in this special group.
Methods: This single-center study included postmenopausal women who received annual health examinations at the First Affiliated Hospital, College of Medicine, Zhejiang University in Zhejiang, China.
Serum Autotaxin Levels Predict Liver-Related Events in Patients With Primary Biliary Cholangitis: A Long-Term Multicenter Observational Study.
Clin Transl Gastroenterol
December 2024
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Article Synopsis
- A study explored the potential of serum autotaxin (ATX) as a predictor for liver-related events (LRE) in patients with primary biliary cholangitis (PBC).
- During a median follow-up of 9.7 years of 190 untreated patients, those with ATX levels ≥1.086 mg/L experienced significantly more LRE compared to those with lower levels (33.3% vs 3.6%).
- The research suggests that ATX is a strong independent predictor for LRE, outperforming existing markers, and aligns with findings from a separate validation cohort of PBC patients.
Serum Autotaxin Level Positively Associates with Metabolic-Associated Fatty Liver Disease and Hyperuricemia in Postmenopausal Women.
Dig Dis
October 2024
Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Introduction: Autotaxin (ATX) is an adipokine known to affect energy metabolism and lipid homeostasis. We aimed to evaluate serum ATX levels in metabolic-associated fatty liver disease (MAFLD) and other metabolic disorders in postmenopausal women.
Methods: Postmenopausal women who received an annual health examination were included.
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma.
Eur J Cancer
December 2024
Scientific Direction, National Institute of Gastroenterology, IRCCS "S. de Bellis" Research Hospital, 70013 Castellana Grotte, BA, Italy. Electronic address:
Article Synopsis
- Early-stage gastric cancer often goes undetected due to a lack of specific symptoms, resulting in late diagnoses and advanced disease, highlighting the need for new biomarkers for early detection and treatment matching.
- The study investigated the prognostic significance of ENPP2/Autotaxin (ATX) and lysophosphatidic acid (LPA) in Gastro-Esophageal Adenocarcinoma (GEA), finding that higher levels of these substances could indicate worse patient outcomes.
- Results showed that while ENPP2 mutations are infrequent, they are linked to lower overall survival, and surgical removal of tumors significantly reduced serum ATX and LPA levels, suggesting potential for targeted therapies based on these biomarkers in future clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!